CA 19-9 has an essential benefit of earlier diagnosis of resectable cancer in asymptomatic persons. When CA 19-9 alone did not succeed in cancer diagnosis, a 13.2% sensitivity spike in pancreatic cancer detection coulb be achieved when markers like LRG1 and TIMP1 were used together with CA 19-9. This evidence concerns the gene LRG1 and familial pancreatic carcinoma.